Work

Phase II study of bendamustine, rituximab, and venetoclax (BR-VEN) for the front-line treatment of Mantle Cell Lymphoma (MCL) in patients ≥60 years old; Updated survival and minimal residual disease (MRD) analysis of precog PrE0405

Year: 2025

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2025-3574

Authors: Craig Portell, Opeyemi Jegede, N. Nora Bennani, Seema Naik, Christopher Reynolds, Priyank Patel, Michael Robertson, Brad Kahl

Institutions: University of Virginia Cancer Center, University of Virginia, Dana-Farber Cancer Institute, Mayo Clinic, Penn State Cancer Institute, Indiana University Health, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Washington University in St. Louis

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4417019111

Cites:

Cited by:

Related to: